Introduction
============

In recent years, the incidence of opportunistic infections has increased in individuals with underlying conditions, autoimmune diseases, cancers, HIV, organ transplantation and chemotherapy. Among opportunistic pathogens, members of actinomycetes order such as *Nocardia, Streptomyces* and *Rhodococcus* need to be identified correctly prior to starting antibiotic therapy ([@R1],[@R2]).

Pulmonary nocardiosis is an invasive infection caused by the genus *Nocardia*, a partial acid-fast microorganism. The common route of pulmonary infection is inhalation of contaminated aerosols from environmental sources. Therefore, the lung is the most common organ involved in nocardiosis. Other entry routes include direct bacterial inoculation of the skin and eyes ([@R1],[@R3]). *Nocardia* species may be transmitted to immunocompromised individuals through contact with environmental sources, leading to various complications, from local cutaneous lesions to disseminated infections ([@R3]).

*Streptomyces spp.* are gram-positive filamentous bacteria that live in a wide range of environmental sources and can produce antimicrobial compounds and secondary metabolites. This group of bacteria may cause opportunistic infections such as pulmonary disease, tuberculosis mimicking, and mycetoma in immunocompromised patients ([@R4]).

*Rhodococcus* spp. are saprophytic members of *Nocardiaceae* that live in environmental sources including soil, dust, decaying plants, milk and animals. The first case of infection with *Rhodococcus equi* was reported in 1967 by Golub *et al.* from lung abscess of a patient with AIDS ([@R5],[@R6]). In addition, there are several clinical reports of human infections with *R. erythropolis, R. ruber*, *R. gordoniae*, and *R. fascians*. However, *R. equi* has been the predominant species causing infections among rhodococci ([@R5],[@R7]). Nowadays, the incidence rate of infections with *Rhodococcus* species are increasing due to an increasing number of individuals with immune-disorders and the development of microbiology methods to detect these bacteria ([@R5],[@R8],[@R9]).

We are at the end of the third decade of the acquired AIDS pandemic ([@R10]). According to the literature, the number of opportunistic infections, particularly aerobic-actinomyces infection in HIV-infected patients has increased ([@R11]). Although, culture is a gold standard method for laboratory diagnosis of bacterial diseases, this method is not robust because of the slow growing of the actinomycete bacteria and complexity of their nutritional requirement ([@R12]). In addition, it cannot differentiate between clinical symptoms of pneumonia; skin, sub-cutaneous and brain abscesses caused by actinomycetes from tuberculosis, viral, fungi infection or malignant tumours ([@R3]). Moreover, the sensitivity of direct smear microscopy and culture is low and controversial as it interferes with prior use of antibiotics before sampling ([@R1],[@R13]). These methods are also time consuming, expensive and need technical skill. Therefore, application of rapid, inexpensive and reliable diagnostic methods is essential for diagnosis and management of these infections. Previously, PCR was used in another study for the diagnosis of these infections in separate single tubes ([@R14],[@R15]). The aim of this study was to design a novel multiplex-PCR assay for simultaneous identification of *Nocardia* and *Streptomyces* and *Rhodococcus* genera infections from broncho-alveolar lavage (BAL) specimens of HIV-infected patients in a single tube.

Materials and Methods
=====================

***Culturing of specimens:*** This study was performed between November 2018 and March 2019 at the Imam Khomeini Complex Hospital (IKH), Tehran University of Medical Sciences (Tehran, Iran). Totally, 29 clinical respiratory specimens including one lung biopsy as well as 28 BAL specimens were collected during routine bronchoscopy from complicated pulmonary infections of HIV patients excluding pulmonary-tuberculosis. The specimens were sent to the Department of Molecular Microbiology laboratory at Tehran University of Medical Sciences immediately and divided into two tubes.

The specimens in the first tube were cultured on brain-heart infusion (BHI) agar medium containing polymyxin B (5 mg/liter), vancomycin (5 mg/liter) and cycloheximide (5 mg/liter) and incubated for 2 to 4 weeks at 30 and 37°C ([@R3]). Direct smear was prepared on slides and specimens were stained with partially acid-fast and Gram staining using the specimens from the first tube. The specimens in the second tube were used for PCR assay.

This study has been approved by the ethical committee of Tehran University of Medical Sciences (approval number, IR.TUMS.MEDICINE.REC.1397.261).

***Primer design:*** The *gyrB* gene sequences were retrieved from NCBI Gene Bank for the various genera including *Dietzia, Gordonia, Mycobacterium, Nocardia, Rhodococcus, Streptomyces,* and *Tsukamurella* to design genus specific primers pairs. Several *gyr*B gene sequences were obtained for every genus. The sequences were analysed by Oligo 5 Software and signature sequences for each genus were selected. A pair of primers was designed for pathogenic genera of *Streptomyces*. By modifications in existing primers, pairs of specific primers were designed for *Nocardia* and *Rhodococcus* equi ([Table 1](#T1){ref-type="table"}) ([@R16],[@R17]).

###### 

Primers designed for *Nocardia* (NR), *Streptomyces* (Stp) and *Rhodococcus equi* (R)

  Primer      Sequence                  Length of product   genus
  ----------- ------------------------- ------------------- ---------------------
  **Stp-F**   GTGCTGTGCCAGAAAGGGCG      320 bp              *Streptomyces* spp.
  **Stp-R**   GCGAGGATCGTGACGTCGAT                          
  **NR-F**    CGACCACAAGGGGGCCTA        596 bp              *Nocardia* spp.
  **NR-R**    GGTTGTAAACCTCTTTCGACAGG                       
  **R-F**     TCCAGAAGCGGGATGAGGAT      707 bp              *Rhodococcus* spp.
  **R-R**     TGGTGTGATGGCGGAAGATC                          

***Specificity of the PCR assay:** Samples used:* DNA from 33 clinical isolates of *Nocardia* species (n=10), *Nocardiopsis* species (n=2), *Streptomyces* species (n=2), *Rhodococcus equi* (n=1), different species of non-tuberculosis mycobacteria (n=4), *Mycobacterium tuberculosis s*(n=2), *Klebsiella pneumoniae* (n=3), *Acinetobacter baumannii* strains (n=3), *Pseudomonas aeruginosa* (n=3), *Staphylococcus aureus* (n=3), *Nocardia cyriacigeorgica* (DSM44484)*, N. asteroids* (ATCC19247) and *N. otitidiscaviarum* (ATCC14629) were tested to determine the specify of the multiplex PCR.

***DNA extraction:*** Chromosomal DNA was extracted using the simple boiling method. In brief, several colonies of bacteria were added to 200 ml TE buffer. Subsequently, the suspension was boiled for 30 min and centrifuged at 11,000 g for 10 min. The supernatant was transferred to another sterile micro tube and centrifuged at 20,000 g for 10 min. The DNA-pellet was resuspended in 50 µl Milli-Q water and stored at -20 °C ([@R3]) for molecular assay.

***PCR amplification:*** PCR was carried out in reaction mixture containing 12.5 µL master mix (Ampliqon Co, Denmark) that contained 1X PCR buffer, 1.5 mM MgCl~2~, 1 µL template DNA (1µg), 0.15 mMdNTP, 1.25 U Taq DNA polymerase, 1µL of each forward and reverse primers ([Table 1](#T1){ref-type="table"}) and sterile distilled water up to 25 µL. PCR was performed in a GenAmp PCR system (BIORAD, USA) according to the following program: predenaturation at 94°C for 5 min followed by 33 cycles each containing denaturation at 94°C for 45 s, annealing at 62°C for 45 s and extension at 72°C for 60 s, followed by a final extension at 72°C for 5 min. In addition, *Nocardia cyriacigeorgica* (DSM44484) was used as a positive control and a mixture reaction containing all of the reagents except template were used as a negative control. The PCR products were loaded on 1.5% agarose gel containing DNA safety and run by electrophoresis for 1 h at 85 V and 25 mA. The gel was visualized under UV trans illuminator after electrophoresis. Finally, the samples positive were sequenced.

***Multiplex PCR and sequencing of clinical samples:*** In total, 1--2 mL of BAL samples was sent to the Department of Molecular Microbiology laboratory after extraction during bronchoscopy ([@R7]). In order to extract DNA from the second tube of BAL specimen, 100 µL of BAL samples was suspended in 250 µL of sterile distilled water and then DNA was extracted using MTB respiratory specimen preparation kit (Invitek, USA).

Multiplex PCR was performed as above using specific primers for the genera of *Nocardia*, *Streptomyces* and *Rhodococcus equi* for direct identification of these pathogens from BAL samples. Positive results from the gel were confirmed by DNA sequencing. Sequences were compared with those stored in GenBank using BLAST alignment software. Similarity greater than 99% was considered as a single species.

***Clinical data collection:*** Patient\'s demographic data such as age, genus, BAL leukocyte count, cotrimoxazole consumption, C-reactive protein, alveolar cavitation and other clinical signs were collected, according to privacy and ethical principles. After sequencing, treatment choices in respect to the bacteria detected were documented, along with the follow-up of the patient (discussed in the *Discussion* section).

Results
=======

***Specificity testing of the method Study population of bacterial samples:*** In total, 28 BAL specimens and one lung biopsy from HIV-infected patients (18 men and 11 women; mean age: 41 years old) were collected by bronchoscopy for diagnosis of aerobic actinomycetes infection (particularly *Nocardiosis*) ([Table 2](#T2){ref-type="table"}). Twelve patients had started therapy by low dosage of co-trimoxazole prophylaxis before sampling of bronchoscopy. All specimens were negative in culture, although two specimens were positive in direct smear microscopy.

###### 

Main characteristics of study population (n=29). BAL, broncho-alveolar lavage. A detailed version of this table is available as *Underlying data*

                                             Multiplex-PCRBALs+lung   Multiplex-PCR BALs+
  ------------------------------------------ ------------------------ ---------------------
  Male                                       15                       3
  Female                                     10                       1
  Median age (years)                         41                       41
  Cotrimoxazole prophylaxis (n)              11                       1
  *Blood tests at time of BAL*                                        
  Median white blood cell count (x1000/µL)   6.2                      7.1
  Median neutrophil count (x1000/µL)         3.7                      5.1
  Median lymphocyte count (x1000/µL          1.6                      1.1
  Median CRP concentration (mg/L)            5.1                      3.2
  PCR result (n)                             25                       4
  *Clinical/radiological presentation (n)*                            
  Pulmonary cavity                           8                        2
  Pulmonary abscess                          1                        2
  Chronic bronchopulmonary                   6                        4
  Brain abscess                              2                        1

***Multiplex PCR assay and sequencing:*** From 29 negative culture specimens, 4 showed positive results in multiplex PCR assay including 3 specimens that were positive for *Nocardia* and one for *Streptomyces* species. The sizes of PCR products were 596 bp (*Nocardia* spp.), 320bp (*Streptomyces* spp.) and 707 bp (*Rhodococcus* spp.) ([Figure 1](#F1){ref-type="fig"}).

![Multiplex-PCR - amplified products in 1% agarose gel; *Nocardia* (596bp), *Streptomyces* (320 bp), *Rhodococcus* (707 bp), and M, molecular size markers (100-bp ladder).](EJHS2906-0737Fig1){#F1}

Sequencing of products (n=4) identified the organisms as *Nocardia cyriacigeorgica* (n=2), *N. farcinica* (n=1) and *Streptomyces albus* (n=1). Among PCR positive patients, 4 were suffering from chronic broncho-pneumonia and one patient had co-infection of *Klebsiella pneumoniae* and *Nocardia cyriacigeorgica.* The results of sequencing confirmed the accuracy of PCR assay (GeneBank accession numbers: MK968270, MK968271, MK968277, MN043685).

***Characteristics of study population and multiplex PCR sensitivity assessment:*** From four PCR positive patients, two were positive in direct smear (partially acid-fast and Gram staining) and took co-trimoxazole before specimen collection. This may be the reason for negative result of culture in this patient. Three other patients did not use antibiotics prior to the specimen collection. All 4 patients were suffering from lung cavitation or lung abscess. One patient had disseminated nocardiosis, which is caused by *Nocardia cyriacigeorgica*. This organism was isolated from both brain abscess and BAL specimens.

Discussion
==========

This study was the first pilot study for direct-detection of *Nocardia, Streptomyces* and *Rhodococcus* genera infections in respiratory clinical specimens using multiplex-PCR method. We detected three cases of infection with *Nocardia* spp. as well as one case of pulmonary infection by *Streptomyces* in HIV-infected patients. The results were confirmed by DNA sequencing. In addition, the sensitivity of this PCR for culture negative samples was demonstrated to be high; the results demonstrated that our primers have high efficiency for identification of *Nocardia* and *Streptomyces* from clinical specimens. It appears that this method is not inhibited by natural inhibitors within the specimens.

The slow growing rate of these organisms, antibiotic consumption before sample collection and time consuming phonotypical tests mean a delay in treatment, which increases the mortality rate among HIV-infected cases ([@R18],[@R19]). Rapid identification in early stages of infection and selection of suitable antibiotics increase the success rate for treatment ([@R20]). Therefore, it is important to use molecular techniques as rapid and accurate methods for identification of these agents from clinical specimens to save the time and improve therapy.

In our study, three nocardiosis patients and one *Streptomyces* infected patients showed symptoms at presentation. One of the patients with nocardiosis, one had used co-trimoxazole before collecting the specimens. In clinical samples (especially cerebral and skin abscesses samples) growth of bacteria can be postponed or inhibited by pre-sampling antibiotic consumption. Molecular tests are independent of bacterial cell growth and could be remedial in correct diagnosis of bacteria. Also, one of the patients in this study had co-infection of *Nocardia* with *Klebsiella pneumoniae*. In previous studies, co-infection of *Nocardia* with other bacterial pathogens was reported in 10--30% of patients ([@R1], [@R21]--[@R22]). *N. cyriacigeorgica* appears to be the most frequent *Nocardia* species isolated from Iranian patients. It is intrinsically resistant to ciprofloxacin, one of the therapeutic choices for respiratory tract infections ([@R23],[@R24]). Early detection of *N. cyriacigeorgica* in clinical samples can lead physicians to choose the correct therapy. Brain abscesses is a lifethreatening infection and with 40--50% mortality ([@R25]). The result of culture for BAL was negative in a patient with brain abscess, while multiplex PCR detected the causative as *N. cycriarogeorgica*. In follow-up, after antinocardiosis treatment of co-trimoxazole, the brain abscess was diminished, indicating that multiplex PCR improved diagnosis and treatment.

In this study, *N. farcinica* strain was detected by multiplex-PCR method, while the culture was negative for the specimen of the same patient. High rate of resistance to antibiotics such as TMPSXT has been reported among *N. farcinica* isolates ([@R26]). Therefore, rapid detection of this species is very important in order to prevent treatment failure. In follow-up, after diagnosis of *N. farcinica*, the treatment was changed from TMP-SXT to imipenem and subsequently the respiratory signs of the patient improved. It has been suggested that recurrence of nocardiosis is common and in several studies it has been shown that recurrence is due to cell wall deficient bacterial cells, which may not be identifiable in culture ([@R27]--[@R29]). Moreover, *Nocardia* infections show similar signs to Parkinson\'s disease ([@R30]--[@R31]); therefore, molecular diagnostic methods can easily identifiy the infectious agent from this nervous system disease.

Pulmonary infection by *Streptomyces* has been increasing due to immune deficiency in recent years ([@R32]). The clinical signs of *Streptomyces* infection mimics tuberculosis ([@R32]), and as there are differences between the methods used for processing and culturing *Streptomyces* and *Mycobacterium tuberculosis*, misdiagnosis of these two infections may occur. This may be complicating treatment as the choices of treatment are also different. In our study *S. albus* infection case showed symptoms similar to tuberculosis (presence of granulomas) ([@R32]). Anti-tuberculosis regimen is not effective for treatment of infection with this bacterium. After getting the positive multiplex-PCR result for *S. albus*, treatment was started using imipenem. Therefore, multiplex-PCR was useful for the timely selection of the correct drug regimen and preventing treatment failure.

Although *Rhodococcus equi* was not detected in our study, it is very important in immune deficiency and people working with animals ([@R9]); one third of patients who are infected by *R. equi* have a history of contact with horses or pigs. Transmission has also been reported during handling and working with clinical samples ([@R5]). Therefore, rapid detection of this bacteria is needed in high risk patients and those in contact with contaminated sources.

Therefore, molecular methods can differentiate these agents that are completely different in laboratory detection and clinical treatment but very similar in clinical signs.

In conclusion, new emerging pathogens such as *Nocardia, Streptomyces* and *Rhodococcus* are being isolated from clinical samples more frequently in recent years due to increases in immune deficiency diseases like HIV infections. Improvement of diagnostic methods in screening and identification of these bacterial infections are highly demanded. *Nocardia* genus has had more attention and been studied more, but *Streptomyces* and *Rhodococcus* species also are increasing. In this study, we designed a novel multiplex PCR for detection of infected cases with *Nocardia*, *Streptomyces* and *Rhodococcus* species for the first time. The results of our study are equivalent or may be better than conventional or current inhouse PCR methods. The high specificity (85.7%) and sensitivity (100%) of this method suggest that the development of this multiplex-PCR is a reliable diagnostic tool for direct detection of *Nocardia, Streptomyces* and *Rhodococcus* infections from BAL and possibly other clinical specimens.
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